Molecular GBM versus Histopathological GBM: Radiology-Pathology-Genetic Correlation and the New WHO 2021 Definition of Glioblastoma

References

1. 1.↵
   1. Guo X,
   2. Gu L,
   3. Li Y, et al

   . Histological and molecular glioblastoma, IDH-wildtype: a real-world landscape using the 2021 WHO classification of CNS tumors. Front Oncol 2023;13:1200815 doi:10.3389/fonc.2023.1200815 pmid:37483487

   CrossRefPubMed
2. 2.↵
   WHO Classification of Tumours. Central Nervous System Tumors. 5th ed. International Agency for Research on Cancer 2022 (beta online version) https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Central-Nervous-System-Tumours-2021
3. 3.↵
   1. Gonzalez Castro LN,
   2. Wesseling P

   . The cIMPACT-NOW updates and their significance to current neuro-oncology practice. Neurooncol Pract 2020;8:4–10 doi:10.1093/nop/npaa055 pmid:33664964

   CrossRefPubMed
4. 4.↵
   1. Louis DN,
   2. Perry A,
   3. Reifenberger G, et al

   . The 2016 World Health Organization Classification of Tumors of the Central Nervous System. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

   CrossRefPubMed
5. 5.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
6. 6.
   1. Dono A,
   2. Wang E,
   3. Rivera V, et al

   . Molecular characteristics, and clinical features of multifocal glioblastoma. J Neurooncol 2020;148:389–97 doi:10.1007/s11060-020-03539-z pmid:32440969

   CrossRefPubMed
7. 7.↵
   1. Dunn GP,
   2. Rinne ML,
   3. Wykosky J, et al

   . Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012;26:756–84 doi:10.1101/gad.187922.112 pmid:22508724

   Abstract/FREE Full Text
8. 8.↵
   1. Melhem JM,
   2. Detsky J,
   3. Lim-Fat MJ, et al

   . Updates in IDH-wildtype glioblastoma. Neurotherapeutics 2022;19:1705–23 doi:10.1007/s13311-022-01251-6 pmid:35641844

   CrossRefPubMed
9. 9.↵
   1. Burdett KB,
   2. Unruh D,
   3. Drumm M, et al

   . Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood 2023;141:1322–36 doi:10.1182/blood.2022017858 pmid:36399711

   CrossRefPubMed
10. 10.↵
    1. Chen L,
    2. Voronovich Z,
    3. Clark K, et al

    . Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 2014;16:1478–83 doi:10.1093/neuonc/nou097 pmid:24860178

    CrossRefPubMed
11. 11.↵
    1. Clara CA,
    2. Marie SK,
    3. de Almeida JR, et al

    . Angiogenesis and expression of PDGF-C, VEGF, CD105 and HIF-1α in human glioblastoma. Neuropathology 2014;34:343–52 doi:10.1111/neup.12111 pmid:24612214

    CrossRefPubMed
12. 12.↵
    Mayo Clinic Laboratories. Molecular and Cytogenetic Testing. https://news.mayocliniclabs.com/oncology/neuro-oncology/ngs-testing/#section2
13. 13.↵
    1. Labussière M,
    2. Di Stefano AL,
    3. Gleize V, et al

    . TERT promoter mutations in gliomas, genetic associations, and clinico-pathological correlations. Br J Cancer 2014;111:2024–32 doi:10.1038/bjc.2014.538 pmid:25314060

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Brennan CW,
    2. Verhaak RG,
    3. McKenna A

    , et al; TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 2013;155:462–77 doi:10.1016/j.cell.2013.09.034 pmid:24120142

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Stichel D,
    2. Ebrahimi A,
    3. Reuss D, et al

    . Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 2018;136:793–803 doi:10.1007/s00401-018-1905-0 pmid:30187121

    CrossRefPubMed
16. 16.↵
    1. Stupp R,
    2. Hegi ME,
    3. Mason WP

    , et al; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66 doi:10.1016/S1470-2045(09)70025-7 pmid:19269895

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Brandes AA,
    2. Tosoni A,
    3. Spagnolli F, et al

    . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008;10:361–67 doi:10.1215/15228517-2008-008 pmid:18401015

    CrossRefPubMed
18. 18.↵
    1. Park CJ,
    2. Han K,
    3. Kim H, et al

    . MRI features may predict molecular features of glioblastoma in isocitrate dehydrogenase wild-type lower-grade gliomas. AJNR Am J Neuroradiol 2021;42:448–56 doi:10.3174/ajnr.A6983 pmid:33509914

    Abstract/FREE Full Text
19. 19.↵
    1. Li Y,
    2. Liu X,
    3. Xu K, et al

    . MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiology 2018;28:356–62 doi:10.1007/s00330-017-4964-z pmid:28755054

    CrossRefPubMed
20. 20.↵
    1. Ivanidze J,
    2. Lum M,
    3. Pisapia D, et al

    . MRI features associated with TERT promoter mutation status in glioblastoma. J Neuroimaging 2019;29:357–63 doi:10.1111/jon.12596 pmid:30644143

    CrossRefPubMed
21. 21.↵
    1. Beig N,
    2. Patel J,
    3. Prasanna P, et al

    . Radiogenomic analysis of hypoxia pathway is predictive of overall survival in glioblastoma. Sci Rep 2018;8:7 doi:10.1038/s41598-017-18310-0 pmid:29311558

    CrossRefPubMed
22. 22.↵
    1. Choi SW,
    2. Cho HH,
    3. Koo H, et al

    . Multi-habitat radiomics unravels distinct phenotypic subtypes of glioblastoma with clinical and genomic significance. Cancers (Basel) 2020;12:1707 doi:10.3390/cancers12071707

    CrossRefPubMed
23. 23.↵
    1. Vamvakas A,
    2. Williams SC,
    3. Theodorou K, et al

    . Imaging biomarker analysis of advanced multiparametric MRI for glioma grading. Phys Med 2019;60:188–98 doi:10.1016/j.ejmp.2019.03.014 pmid:30910431

    CrossRefPubMed